CASP9 is an initiator caspase in the intrinsic apoptosis pathway, but has a dominant-negative short isoform.
| Isoform | UniProt ID | Synonym | Key Feature | Function |
|---|---|---|---|---|
| Isoform 1 | P55211-1 | 9L, Alpha | Full-length, catalytically active | INDUCES APOPTOSIS |
| Isoform 2 | P55211-2 | 9S, Beta | Lacks catalytic domain | DOMINANT-NEGATIVE INHIBITOR |
| Isoform 3 | P55211-3 | Gamma | - | Unknown |
| Isoform 4 | P55211-4 | - | - | Unknown |
Caspase-9L (Isoform 1):
- Contains CARD domain for Apaf-1 binding
- Contains catalytic domain
- Forms apoptosome with Apaf-1 and cytochrome c
- Cleaves and activates CASP3/CASP7
- PRO-APOPTOTIC
Caspase-9S (Isoform 2):
UniProt explicitly states:
"Lacks activity is an dominant-negative inhibitor of caspase-9" PMID:10070954
Mechanism: Caspase-9S competes with Caspase-9L for Apaf-1 binding but cannot activate downstream caspases.
Apaf-1 + Cyt c + dATP → Apoptosome
If Caspase-9L binds: → Apoptosis
If Caspase-9S binds: → No apoptosis (dominant-negative)
The ratio of 9L/9S determines apoptotic sensitivity.
Like BCL2L1, this is a case where the balance between isoforms determines cell fate:
- High 9L/9S ratio → apoptosis-sensitive
- Low 9L/9S ratio → apoptosis-resistant
Cancer cells often shift this ratio towards 9S to evade apoptosis.